Janssen Pharmaceutica Nv

Jan L Sechler

Dana L Johnson

Robert W Tuman

Tianbao Lu

Kristi A Leonard

Maxwell David Cummings

Thomas P Markotan

Richard Scott Alexander

Richard William Connors

Robert A Galemmo

Anna C Maroney

Jeremy Mark Travins

Donald William Ludovici

Chih Yung Ho

Stuart Emanuel

Robert A Galemmo, Jr

Umar Maharoof

Heather Rae Hufnagel

Eric D Strobel

Ehab Khalil

Jay Mei

Bengt Anders Brunmark

Hwa Kwo Yen

The invention is directed to triazolopyridazine compounds of Formula I: where R, R, R, R, R, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Triazolopyridazine compounds

Triazolopyridazines as kinase modulators

The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.

N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders

The invention is directed to acylhydrazones compounds of Formula I: where R, Rand A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Acylhydrazones as kinase modulators

N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders

Growing community of inventors

Doylestown, PA, United States of America

Jan L Sechler